A Phase 1, Randomized, First-in-human, Open-label Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core) in HIV-1 Uninfected Adults in Good General Health
Latest Information Update: 07 May 2024
At a glance
- Drugs MRNA-1644 (Primary)
- Indications HIV infections
- Focus Adverse reactions; First in man
- 29 Apr 2024 Planned End Date changed from 1 Jul 2023 to 1 Jul 2024.
- 08 Mar 2023 Planned End Date changed from 11 Apr 2023 to 1 Jul 2023.
- 08 Mar 2023 Planned primary completion date changed from 11 Apr 2023 to 1 Jul 2023.